Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq as soon as next year.

Approval for second-line or later patients with metastatic castration-resistant prostate cancer (mCRPC) would offer a new choice following use of a novel therapy such as Xtandi enzalutamide or Zytiga abiraterone. Treatments include chemotherapy, radiotherapy or Provenge sipuleucel-T, according to National Comprehensive Cancer Network treatment guidelines (see “Prostate Cancer Disrupted”)...